HEMOGENYX PHARMACEUTICALS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.585 GBX | -1.43% |
|
-5.15% | -31.09% |
| Apr. 25 | EARNINGS: LSL starts 2024 "strongly"; Focusrite maintains payout | AN |
| Apr. 25 | Hemogenyx Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
| Sales 2021 | - | Sales 2022 | - | Capitalization | 12.98M |
|---|---|---|---|---|---|
| Net income 2021 | -5M | Net income 2022 | -3M | EV / Sales 2021 | - |
| Net cash position 2021 | 6.83M | Net Debt 2022 | 890K | EV / Sales 2022 | - |
| P/E ratio 2021 |
-2.85
x | P/E ratio 2022 |
-3.26
x | Employees | 14 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 89.27% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.43% | ||
| 1 week | -5.15% | ||
| Current month | -9.94% | ||
| 1 month | -7.98% | ||
| 3 months | -45.34% | ||
| 6 months | -22.68% | ||
| Current year | -31.09% |
1 week
1.53
1.70
1 month
1.531.80
Current year
1.537.13
1 year
1.107.13
3 years
1.057.13
5 years
0.9515.39
10 years
0.9515.39
| Managers | Title | Age | Since |
|---|---|---|---|
Alexis Sandler
FOU | Founder | - | 12-12-31 |
| Founder | 59 | 12-12-31 | |
van Besien Koen
CTO | Chief Tech/Sci/R&D Officer | - | 22-08-09 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Peter Redmond
BRD | Director/Board Member | 76 | - |
Marc Feldmann
CHM | Chairman | 79 | 18-04-08 |
| Founder | 59 | 12-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 1.585 | -1.43% | 5,559,012 |
| 24-04-24 | 1.608 | -1.29% | 5,063,450 |
| 24-04-23 | 1.629 | +0.87% | 4,149,071 |
| 24-04-22 | 1.615 | -1.58% | 5,660,865 |
| 24-04-19 | 1.641 | -1.80% | 5,990,463 |
Delayed Quote London S.E., April 25, 2024 at 11:35 am EDT
More quotes
Hemogenyx Pharmaceuticals plc is a preclinical-stage biotechnology company. The Company is focused on the discovery, development and commercialization of treatments relating to bone marrow/hematopoietic (blood-forming) stem cell (BM/HSC) transplants for blood diseases, including leukemia, lymphoma and bone marrow failure and viral infections. It is developing several distinct and complementary product candidates, as well as a platform technology. To obviate the use of chemotherapeutic agents for conditioning of patients undergoing BM/HSC transplantations, the Company developed a method of selective elimination of hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in patients using highly specific CDX antibodies. It has developed postnatal human hemogenic endothelial cells (Hu-PHEC cells) to generate cancer-free hematopoietic stem cells (HSC) for use in transplants to treat blood cancers. It has developed HEMO-CAR-T, for the potential treatment of acute myeloid leukemia (AML).
Calendar
2024-04-28
- Q4 2023 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -31.09% | 26.82M | |
| -2.26% | 104B | |
| +1.41% | 97.42B | |
| +0.79% | 22.2B | |
| -17.84% | 21.23B | |
| -11.11% | 18.33B | |
| -42.83% | 16.35B | |
| -17.63% | 15.06B | |
| +4.55% | 13.98B | |
| +32.11% | 11.66B |
- Stock Market
- Equities
- SILF Stock
